IBM has been a cornerstone of technological innovation for over a century, pioneering advancements in computing, artificial intelligence, and enterprise solutions. Despite its early dominance, IBM struggled to maintain its competitive edge in the evolving tech landscape, facing setbacks in personal computing, software, and AI adoption. This case study examines IBM’s historical rise, the challenges that led to its decline, and its strategic attempts at revival, with a particular focus on its AI-driven oncology tool, Watson. IBM Watson for Oncology was introduced as a groundbreaking AI solution for cancer diagnosis and treatment. However, its reliance on hypothetical data rather than real-world patient cases, lack of transparency in decision-making, and inability to integrate seamlessly with medical practices led to skepticism among healthcare professionals. This case study analyzes Watson’s failure as a cautionary tale for AI in healthcare and explores IBM’s broader struggle to reclaim technological leadership .The study was conducted through a comprehensive review of IBM’s market position, AI initiatives, leadership decisions, and real-world case studies of Watson in oncology. Key findings highlight IBM’s inability to sustain innovation, AI adoption challenges, and difficulties in cloud computing competition. Despite investments in AI and restructuring efforts-including a 2020 corporate split-IBM continues to lag behind major tech rivals. This study underscores the importance of real-world data integration, transparent AI models, and strategic adaptability in ensuring AI success in healthcare and beyond. IBM’s future depends on its ability to merge historical strengths with emerging technologies while navigating an increasingly competitive market.